240 related articles for article (PubMed ID: 31388629)
1. Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents.
Hernandez ED; Zheng L; Kim Y; Fang B; Liu B; Valdez RA; Dietrich WF; Rucker PV; Chianelli D; Schmeits J; Bao D; Zoll J; Dubois C; Federe GC; Chen L; Joseph SB; Klickstein LB; Walker J; Molteni V; McNamara P; Meeusen S; Tully DC; Badman MK; Xu J; Laffitte B
Hepatol Commun; 2019 Aug; 3(8):1085-1097. PubMed ID: 31388629
[TBL] [Abstract][Full Text] [Related]
2. Hammerhead-type FXR agonists induce an enhancer RNA
Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
Elife; 2024 Apr; 13():. PubMed ID: 38619504
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
[TBL] [Abstract][Full Text] [Related]
4. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
6. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
7. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
8. Hammerhead-type FXR agonists induce an eRNA
Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper JK
bioRxiv; 2024 Feb; ():. PubMed ID: 38045226
[TBL] [Abstract][Full Text] [Related]
9. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
14. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
[TBL] [Abstract][Full Text] [Related]
15. A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis.
Xiao Y; Wang Y; Liu Y; Wang W; Tian X; Chen S; Lu Y; Du J; Cai W
Liver Int; 2021 Sep; 41(9):2117-2131. PubMed ID: 33894097
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Anfuso B; Tiribelli C; Adorini L; Rosso N
Sci Rep; 2020 Feb; 10(1):1699. PubMed ID: 32015483
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice.
Li S; Zhuge A; Wang K; Xia J; Wang Q; Han S; Shen J; Li L
Front Pharmacol; 2022; 13():1081553. PubMed ID: 36588706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
